source
- Edgewise Therapeutics' experimental heart drug meets Phase 2 endpoints in cardiomyopathy trialEdgewise Therapeutics reported that its oral candidate EDG-7500 achieved the predefined goals of a Phase 2 study in both obstructive and non‑obstructive hypertrophic cardiomyopathy. The trial demo…
- FDA approves OTC naloxone nasal spray Rextovy, expanding consumer access to overdose treatmentThe FDA announced approval of a new over-the-counter naloxone nasal spray called Rextovy, delivering 4 mg of naloxone hydrochloride for emergency reversal of opioid overdose. The product can be pu…